Trial reportBMC cancer2009
Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.
Trial report in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continuous 5-fluorouracil Infusion Plus Long Acting Octreotide in Advanced Well Differentiated Neuroendocrine Carcinomas. A Phase II Trial of the Piemonte Oncology Network.
Phase II Study of the Combination of Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Inoperable Well-Differentiated Neuroendocrine Tumors
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.Journal of cancer research and clinical oncology · 2015Pooled it
- Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.Cancer science · 2018Trial
- Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours.European journal of nuclear medicine and molecular imaging · 2015Trial
- Trial
- Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.British journal of cancer · 2011Trial
- Systemic therapy for gastroenteropancreatic neuroendocrine neoplasms: current landscape and future directions.Therapeutic advances in medical oncology · 2026Review
- Review
- From biology to clinical practice: antiproliferative effects of somatostatin analogs in neuroendocrine neoplasms.Therapeutic advances in medical oncology · 2024Review
- Metronomic chemotherapy in patients with advanced neuroendocrine tumors: A single-center retrospective analysis.Journal of neuroendocrinology · 2022Article
- Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review.Journal of gastrointestinal oncology · 2021Article
- [Systemic Therapy for Low-grade Pulmonary Neuroendocrine Tumor].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Chromogranin A: From Laboratory to Clinical Aspects of Patients with Neuroendocrine Tumors.International journal of endocrinology · 2018Review
- Chemotherapy in NETs: When and how.Reviews in endocrine & metabolic disorders · 2017Review
- Neuroendocrine tumors of the thymus: the oncologist point of view.Journal of thoracic disease · 2017Review
- The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma.Journal of gastrointestinal oncology · 2014Article
- Metronomic chemotherapy.Journal of pharmacology & pharmacotherapeutics · 2014Review
- Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review.BMC cancer · 2014Article
- Response assessment in metronomic chemotherapy: RECIST or PERCIST?Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India · 2014Article
- Peptide receptor radionuclide therapy for neuroendocrine tumours: standardized and randomized, or personalized?European journal of nuclear medicine and molecular imaging · 2014Article
- Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan.Ecancermedicalscience · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWell-differentiated neuroendocrine carcinomas are highly vascularized and may be sensitive to drugs administered on a metronomic schedule that has shown antiangiogenic properties. A phase II study was designed to test the activity of protracted 5-fluorouracil (5FU) infusion plus long-acting release (LAR) octreotide in patients with neuroendocrine carcinoma.
methodsTwenty-nine patients with metastatic or locally advanced well-differentiated neuroendocrine carcinoma were treated with protracted 5FU intravenous infusion (200 mg/m2 daily) plus LAR octreotide (20 mg monthly). Patients were followed for toxicity, objective response, symptomatic and biochemical response, time to progression and survival.
resultsAssessment by Response Evaluation Criteria in Solid Tumors (RECIST) criteria showed partial response in 7 (24.1%), stable disease in 20 (69.0%), and disease progression in 2 patients. Response did not significantly differ when patients were stratified by primary tumor site and proliferative activity. A biochemical (chromogranin A) response was observed in 12/25 assessable patients (48.0%); symptom relief was obtained in 9/15 symptomatic patients (60.0%). There was non significant decrease in circulating vascular epithelial growth factor (VEGF) over time. Median time to progression was 22.6 months (range, 2.7-68.5); median overall survival was not reached yet. Toxicity was mild and manageable.
conclusionContinuous/metronomic 5FU infusion plus LAR octreotide is well tolerated and shows activity in patients with well-differentiated neuroendocrine carcinoma. The potential synergism between metronomic chemotherapy and antiangiogenic drugs provides a rationale for exploring this association in the future.
trial registrationNCT00953394.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.